Association Between T2-related Comorbidities and Effectiveness of Biologics in Severe Asthma
Wechsler et al examine the association between type 2-related comorbidities and biologic agent effectiveness in adults with severe asthma (SA). They used International Severe Asthma Registry data from 21 countries (2017-2022) to quantify changes in four outcomes before and after biologic therapy in...
Saved in:
Published in | American journal of respiratory and critical care medicine Vol. 209; no. 3; p. 262 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
New York
American Thoracic Society
01.02.2024
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Wechsler et al examine the association between type 2-related comorbidities and biologic agent effectiveness in adults with severe asthma (SA). They used International Severe Asthma Registry data from 21 countries (2017-2022) to quantify changes in four outcomes before and after biologic therapy in patients with or without allergic rhinitis, chronic rhinosinusitis (CRS) with or without nasal polyps (NPs), NPs, or eczema-atopic dermatitis. The findings highlight the importance of systematic comorbidity evaluation. The presence of CRS with or without NPs or NPs alone may be considered a predictor of the effectiveness of biologic agents in SA patients. |
---|---|
ISSN: | 1073-449X 1535-4970 |
DOI: | 10.1164/rccm.202301-0067OC |